|
US9249423B2
(en)
|
2007-02-02 |
2016-02-02 |
Yale University |
Method of de-differentiating and re-differentiating somatic cells using RNA
|
|
US10155038B2
(en)
|
2007-02-02 |
2018-12-18 |
Yale University |
Cells prepared by transient transfection and methods of use thereof
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
CN104411819B
(zh)
*
|
2012-06-11 |
2019-05-10 |
威尔逊沃夫制造公司 |
用于过继细胞疗法的改进的细胞培养方法
|
|
IN2015KN00329A
(https=)
|
2012-08-09 |
2015-07-10 |
Univ Leland Stanford Junior |
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
SG11201507026WA
(en)
*
|
2013-02-06 |
2015-10-29 |
Anthrogenesis Corp |
Modified t lymphocytes having improved specificity
|
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
AU2014240083C1
(en)
|
2013-03-15 |
2019-10-24 |
Celgene Corporation |
Modified T lymphocytes
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
CA2909701C
(en)
*
|
2013-04-17 |
2022-12-06 |
Baylor College Of Medicine |
Immunosuppressive tgf-.beta. signal converter
|
|
WO2014201319A1
(en)
*
|
2013-06-14 |
2014-12-18 |
The University Of Houston System |
Targeting tumor neovasculature with modified chimeric antigen receptors
|
|
EP3021853A1
(en)
*
|
2013-07-18 |
2016-05-25 |
Baylor College Of Medicine |
Method of enhancing potency of immune cells
|
|
WO2015042705A1
(en)
|
2013-09-24 |
2015-04-02 |
Medicenna Biopharma Inc. |
Interleukin-4 receptor-binding fusion proteins and uses thereof
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
KR20160145802A
(ko)
*
|
2014-04-23 |
2016-12-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
KR20170037625A
(ko)
|
2014-07-21 |
2017-04-04 |
노파르티스 아게 |
Cll-1 키메라 항원 수용체를 사용한 암의 치료
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
JP6631865B2
(ja)
*
|
2014-08-11 |
2020-01-15 |
日本化薬株式会社 |
ＴＧＦβ阻害機能を持つキメラタンパク質
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
KR20170068504A
(ko)
|
2014-10-08 |
2017-06-19 |
노파르티스 아게 |
키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
|
|
MA41538A
(fr)
*
|
2014-10-17 |
2017-12-26 |
Baylor College Medicine |
Cellules immunitaires bipartites et tripartites de signalisation
|
|
CA3197849A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US10828353B2
(en)
*
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CA2978186A1
(en)
|
2015-03-05 |
2016-09-09 |
Fred Hutchinson Cancer Research Center |
Immunomodulatory fusion proteins and uses thereof
|
|
IL294055A
(en)
*
|
2015-03-20 |
2022-08-01 |
Childrens Nat Medical Ct |
Generating virus or other antigen-specific t cells from a naive t cell population
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CN104910279B
(zh)
*
|
2015-06-05 |
2019-02-22 |
重庆精准生物技术有限公司 |
靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
GB201514875D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
GB201518816D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Receptor
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
EP3393504B1
(en)
|
2015-12-22 |
2025-09-24 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
US11325948B2
(en)
|
2016-03-19 |
2022-05-10 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
|
|
US11111505B2
(en)
|
2016-03-19 |
2021-09-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing lymphocytes and regulating the activity thereof
|
|
IL261713B2
(en)
*
|
2016-03-19 |
2023-09-01 |
F1 Oncology Inc |
Methods and preparations for the transfer of lymphocytes and their regulated expansion
|
|
US12590321B2
(en)
|
2016-03-19 |
2026-03-31 |
Exuma Biotech Corp. |
Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
SG11201901642XA
(en)
*
|
2016-08-26 |
2019-03-28 |
Baylor College Medicine |
Constitutively active cytokine receptors for cell therapy
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
IL266628B2
(en)
|
2016-11-17 |
2024-06-01 |
Bluebird Bio Inc |
TGFBeta signal converter
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
GB201702617D0
(en)
*
|
2017-02-17 |
2017-04-05 |
Autolus Ltd |
Receptor
|
|
AU2018226884B2
(en)
*
|
2017-03-03 |
2024-11-07 |
Exuma Biotech, Corp. |
Methods and compositions for transducing and expanding lymphocytes and regulating the activity thereof
|
|
AU2018236461B2
(en)
|
2017-03-17 |
2025-03-27 |
Fred Hutchinson Cancer Center |
Immunomodulatory fusion proteins and uses thereof
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP4317422A3
(en)
|
2017-04-13 |
2024-05-01 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
WO2019073299A1
(en)
|
2017-10-10 |
2019-04-18 |
Medicenna Therapeutics, Inc. |
IL-4 FUSION FORMULATIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
WO2019109980A1
(zh)
*
|
2017-12-06 |
2019-06-13 |
科济生物医药（上海）有限公司 |
嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
WO2019169290A1
(en)
*
|
2018-03-02 |
2019-09-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
WO2019232523A1
(en)
*
|
2018-06-01 |
2019-12-05 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
|
|
WO2019239213A2
(en)
|
2018-06-01 |
2019-12-19 |
Medicenna Therapeutics Inc. |
Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CN110615843B
(zh)
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含第三信号受体的嵌合抗原受体及其应用
|
|
SG11202103317XA
(en)
|
2018-10-17 |
2021-05-28 |
Senti Biosciences Inc |
Combinatorial cancer immunotherapy
|
|
US11419898B2
(en)
|
2018-10-17 |
2022-08-23 |
Senti Biosciences, Inc. |
Combinatorial cancer immunotherapy
|
|
US20200147137A1
(en)
*
|
2018-11-08 |
2020-05-14 |
WUGEN, Inc. |
Compositions and methods for treatment of cancer
|
|
CN109735558B
(zh)
*
|
2018-12-12 |
2022-04-15 |
中南大学 |
一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
|
|
EP3931208A1
(en)
*
|
2019-03-01 |
2022-01-05 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors bearing a pd-1 ectodomain
|
|
BR112021017365A2
(pt)
|
2019-03-01 |
2022-02-01 |
Allogene Therapeutics Inc |
Receptores de citocina quiméricos constitutivamente ativos
|
|
KR20220030933A
(ko)
|
2019-05-08 |
2022-03-11 |
메디진 이뮤노테라피스 게엠바하 |
조작된 t 세포
|
|
AU2020336992A1
(en)
|
2019-08-30 |
2022-04-14 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
WO2021041806A1
(en)
|
2019-08-30 |
2021-03-04 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors comprising tgf beta binding domains
|
|
KR102275668B1
(ko)
*
|
2019-09-26 |
2021-07-12 |
충북대학교 산학협력단 |
면역신호의 변환이 가능한 키메릭 사이토카인 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
JP2023514407A
(ja)
|
2020-02-24 |
2023-04-05 |
アロジーン セラピューティクス，インコーポレイテッド |
増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞
|
|
CN115427440A
(zh)
|
2020-02-25 |
2022-12-02 |
圭尔医疗有限公司 |
用于工程化细胞的嵌合受体
|
|
CA3193424A1
(en)
|
2020-08-31 |
2022-03-03 |
Yale University |
Compositions and methods for delivery of nucleic acids to cells
|
|
US20230265147A1
(en)
*
|
2021-09-17 |
2023-08-24 |
The Trustees Of The University Of Pennsylvania |
Interleukin-9 Signaling in Chimeric Antigen Receptor (CAR) Immune Cells
|
|
CN119546328A
(zh)
|
2022-04-08 |
2025-02-28 |
再生元制药公司 |
多部分受体和信号传导复合物
|
|
AU2023406926A1
(en)
|
2022-12-01 |
2025-06-26 |
Yale University |
Stimuli-responsive traceless engineering platform for intracellular payload delivery
|
|
CN120225568A
(zh)
*
|
2022-12-27 |
2025-06-27 |
广州瑞风生物科技有限公司 |
一种融合蛋白及其应用
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
KR20250169635A
(ko)
|
2023-01-23 |
2025-12-03 |
메디치니쉐 호흐슐레 하노버 |
항-entpd3 키메라 항원 수용체
|
|
IL322333A
(en)
|
2023-02-07 |
2025-09-01 |
Quell Therapeutics Ltd |
Culture method for TREG cells
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4669343A1
(en)
|
2023-02-24 |
2025-12-31 |
Medizinische Hochschule Hannover |
CHIMERIC ANTIGEN RECIPIENT
|
|
CN116284449B
(zh)
*
|
2023-02-27 |
2024-11-19 |
深圳市先康达生命科学有限公司 |
增强型TGF-βR嵌合受体及其应用
|
|
KR20250158048A
(ko)
|
2023-03-03 |
2025-11-05 |
아스널 바이오사이언시스, 인크. |
Psma 및 ca9을 표적으로 하는 시스템
|
|
EP4680728A1
(en)
|
2023-03-17 |
2026-01-21 |
Quell Therapeutics Limited |
Treg therapy
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN121586582A
(zh)
|
2023-03-20 |
2026-02-27 |
汉诺威医学院 |
嵌合抗原受体
|
|
WO2024193687A1
(en)
*
|
2023-03-23 |
2024-09-26 |
Nanjing Legend Biotech Co., Ltd. |
Inverted cytokine receptors and methods of use thereof
|
|
AU2024243972A1
(en)
*
|
2023-04-06 |
2025-10-23 |
Memorial Hospital For Cancer And Allied Diseases |
Il-10 receptor antibodies and methods of use thereof
|
|
CN116496417B
(zh)
*
|
2023-06-27 |
2023-10-10 |
北京市肿瘤防治研究所 |
含有膜型il7的融合蛋白及t细胞
|
|
WO2025016399A1
(en)
*
|
2023-07-17 |
2025-01-23 |
Nanjing Legend Biotech Co., Ltd. |
Fusion proteins and methods of use thereof
|
|
WO2026008994A1
(en)
|
2024-07-04 |
2026-01-08 |
Quell Therapeutics Limited |
Expression construct
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|